help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kopin, I. J.
Right arrow Articles by Ebert, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kopin, I. J.
Right arrow Articles by Ebert, M. H.

Journal of Clinical Endocrinology & Metabolism, Vol 57, 632-637, Copyright © 1983 by Endocrine Society

ARTICLES

Urinary catecholamine metabolites distinguish different types of sympathetic neuronal dysfunction in patients with orthostatic hypotension

IJ Kopin, RJ Polinsky, JA Oliver, IR Oddershede and MH Ebert

Urinary excretion rates of the major norepinephrine metabolites, 3- methoxy-4-hydroxymandelic acid, 3-methoxy-4-hydroxy-phenylglycol and normetanephrine, were determined in 12 normal subjects and 23 patients with neurogenic orthostatic hypotension due to either multiple system atrophy [Shy-Drager Dyndrome (MSA)] or idiopathic orthostatic hypotension (IOH). There were striking and parallel decreases in all catecholamine metabolites in IOH consistent with loss of peripheral sympathetic nerves. Patients with MSA excreted greater amounts of the deaminated metabolites than did the patients with IOH, but most excreted equally low amounts of normetanephrine. The disproportionate decrease in excretion of normetanephrine by patients with MSA is consistent with observations in experimental animals that O-methylation is the primary metabolic route for active released norepinephrine, whereas deamination is the predominant metabolic route for intraneuronal degradation of the catecholamine. The similar proportional decreases in all catecholamine metabolites in patients with IOH (who have no central nervous system deficit) indicates that brain norepinephrine is a source of only a small fraction of urinary norepinephrine metabolites, including 3-methoxy-4-hydroxy-phenylglycol.


This article has been cited by other articles:


Home page
 DiabetesHome page
R. D. Hoeldtke, K. D. Bryner, G. G. Horvath, R. W. Phares, L. F. Broy, and G. R. Hobbs
Redistribution of Sudomotor Responses Is an Early Sign of Sympathetic Dysfunction in Type 1 Diabetes
Diabetes, February 1, 2001; 50(2): 436 - 443.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. D. Hoeldtke, K. D. Bryner, P. Komanduri, I. Christie, G. Ganser, and G. R. Hobbs
Decreased Prorenin Processing Develops before Autonomic Dysfunction in Type 1 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 585 - 589.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society